Clinical Commander

Back to dossier
cardio.acute-hf.iatrogenic-hypothyroid.v1PRODUCTION
cardio.acute-hf.iatrogenic-hypothyroid.v1

Acute HF — Iatrogenic hypothyroid (post-thyroidectomy / post-RAI / over-treated thionamide)

cardiologyacuteadult
Hard-required inputs
0 / 13
Care setting:

Encounter flow

10/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Iatrogenic hypothyroid HF = thyroid hormone deficiency from thyroidectomy / RAI / over-treated thionamide / central pituitary cause; impaired myocardial relaxation + reduced CO + bradycardia + pericardial effusion + hyperlipidemia accelerating CAD; severe form = myxedema coma (mortality 30-60%)

Inputs
3
Actions
0
Advance rule
Set
Advance when

iatrogenic etiology + biochemical hypothyroid confirmed

Patient inputs (14)

Elderly patients more vulnerable to myxedema coma + require lower starting levothyroxine dose due to CAD/arrhythmia risk

Identifies iatrogenic trigger: thyroidectomy date, RAI date for Graves, thionamide agent + dose + duration; replacement adherence

Replacement dose vs ideal weight-based (1.6 µg/kg ideal body weight in adults); adherence; recent dose changes; PPI / iron / calcium interactions impair absorption

eGFR for fluid management + medication dosing; rhabdomyolysis can elevate Cr

TSH primary screen — markedly elevated >50 mIU/L in primary hypothyroid; LOW or inappropriately normal in central hypothyroid (post-pituitary surgery / radiation / sunitinib / bexarotene)

Free T4 confirms biochemical hypothyroid; helps distinguish from sick euthyroid syndrome; trend during treatment

Cortisol to rule out concurrent adrenal insufficiency (5-10% in myxedema coma; thyroid replacement without cortisol can precipitate adrenal crisis); ACTH stim if concerning

Hyponatremia common in severe hypothyroid; impaired free water excretion + SIADH-like mechanism; affects fluid + diuretic strategy

Hypothyroid myopathy + rhabdomyolysis common; CK elevation can be marked

ECG: sinus bradycardia, low voltage, prolonged QT, J wave in myxedema; AV block possible

Echo: pericardial effusion common (may be hemodynamically significant), impaired relaxation, possible reduced LVEF in severe; screen for tamponade physiology

Hypothermia is hallmark of myxedema coma; passive rewarming preferred over active

Hypotension in myxedema coma (decreased CO + adrenal insufficiency overlap); guides pressor + cortisol decision

Hypothyroid hypercholesterolemia accelerates CAD; informs cardiac risk + statin

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (4)

4 need judgement
  • informationallife_threateningmyxedema_coma_with_shock
    Iatrogenic hypothyroid patient with hypothermia + altered mentation + bradycardia + hypotension + hyponatremia — myxedema coma with shock (mortality 30-60%)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningconcurrent_adrenal_insufficiency_overlap
    Iatrogenic hypothyroid patient with concurrent adrenal insufficiency (5-10% in myxedema coma; central hypothyroid with pituitary cause has high overlap)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningsevere_hyponatremia_worsening_during_treatment
    Sodium <120 mEq/L with seizure or neurologic symptoms in myxedema patient OR rapid sodium correction (>8 mEq/24h) with osmotic demyelination risk
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverelevothyroxine_overshoot_with_arrhythmia
    Excessive levothyroxine dose (or rapid replacement) precipitating tachyarrhythmia (AF, VT) or angina in elderly / CAD patient
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RED_FLAGSrequiredDrives risk stratification
Loading…

Recommended regimen

Iatrogenic hypothyroid HF — STEROID FIRST then T4 replacement, cautious diuresis (mucinous edema not true volume), rate support, ADHF backbone
axis: iatrogenic_hypothyroid_hf_phenotype
Selected axis "Iatrogenic hypothyroid HF — STEROID FIRST then T4 replacement, cautious diuresis (mucinous edema not true volume), rate support, ADHF backbone" by default fallback (first axis)
  • hydrocortisone
    first line
    glucocorticoid_short_acting
    100 mg IV q8h until adrenal insufficiency excluded • IV • q8h
    triggers: suspected_or_confirmed_myxedema_coma, iatrogenic_hypothyroid_with_unknown_adrenal_status
    ATA 2014 PMID 25266247 + Wartofsky myxedema management — MANDATORY before thyroid replacement; 5-10% concurrent adrenal insufficiency; T4 without cortisol can precipitate adrenal crisis
    rxcui 5492
  • levothyroxine
    first line
    thyroid_hormone_replacement
    200-500 µg IV LOAD (lower 100-200 µg if elderly/CAD/AF) then 50-100 µg IV daily until tolerating PO; PO maintenance 1.6 µg/kg IBW • IV • daily
    triggers: iatrogenic_hypothyroid_hf, myxedema_coma
    ATA 2014 PMID 25266247 — IV loading for myxedema; oral replacement once stable; titrate to TSH 0.5-2.5 in young, 0.5-4.0 in elderly
    rxcui 10582
  • liothyronine (T3)
    second line
    thyroid_hormone_t3
    5-20 µg IV q8h adjunct (controversial; consider in severe myxedema coma) • IV • q8h
    triggers: severe_myxedema_coma_with_inadequate_t4_response
    Wartofsky — adjunctive T3 may speed conversion in severe cases but increases cardiac risk; use cautiously in elderly/CAD
    rxcui 10814
  • furosemide
    first line
    loop_diuretic
    20-40 mg IV bolus (LOWER than usual due to mucinous edema not true volume + hyponatremia risk) • IV • as needed
    triggers: hypothyroid_hf_with_pulmonary_edema_after_volume_assessment
    Cautious diuresis — peripheral edema in hypothyroid is often mucinous not volume; over-diuresis worsens hyponatremia + cardiac strain; DOSE PMID 21366472 strategy adapted
    rxcui 4603
  • normal saline 0.9%
    first line
    crystalloid
    500 mL IV bolus over 30 min cautiously, then 75-100 mL/h maintenance • IV • as needed
    triggers: hypothyroid_hf_with_hypotension_and_no_pulmonary_edema
    Cautious crystalloid for hypotension; avoid free water due to hyponatremia; consider 3% saline if Na <120 with seizures
    rxcui 9863
  • norepinephrine
    first line
    vasopressor_alpha_beta
    0.05-0.5 µg/kg/min titrate to MAP ≥65 (often poorly responsive until thyroid + cortisol replacement) • IV • continuous
    triggers: myxedema_coma_with_shock_after_steroid
    SOAP-II PMID 20200382; vasopressor responsiveness improves with thyroid + cortisol replacement; may need higher than usual doses
    rxcui 7512
  • atropine
    first line
    anticholinergic_muscarinic_antagonist
    0.5-1 mg IV q3-5 min up to 3 mg • IV • as needed
    triggers: symptomatic_bradycardia_in_myxedema
    AHA ACLS bradycardia algorithm; bridge to thyroid replacement / pacing
    rxcui 1223
  • isoproterenol
    second line
    beta_agonist
    2-10 µg/min IV titrate • IV • continuous
    triggers: symptomatic_bradycardia_refractory_to_atropine
    Beta-1 agonist bridge for refractory bradycardia until pacing or thyroid replacement effect
    rxcui 6054
  • carvedilol
    first line
    beta_alpha_blocker
    3.125 mg PO BID titrate (DEFER until euthyroid + no bradycardia) • PO • BID
    triggers: euthyroid_status_achieved_with_persistent_lvef_below_40
    GDMT for persistent HFrEF; DEFER initiation until thyroid replacement complete + bradycardia resolved (BB worsens bradycardia in active hypothyroid); CAPRICORN PMID 11356436
    rxcui 20352
  • sacubitril-valsartan
    first line
    arni
    24/26 mg PO BID titrate (DEFER until euthyroid + stable hemodynamics) • PO • BID
    triggers: euthyroid_with_persistent_lvef_below_40
    PIONEER-HF PMID 30403955; defer initiation until after thyroid replacement to avoid hypotension layering
    rxcui 1656328
  • spironolactone
    first line
    mra
    12.5-25 mg PO daily • PO • daily
    triggers: euthyroid_persistent_lvef_below_40_k_below_5_egfr_above_30
    RALES PMID 10471456; once euthyroid + stable
    rxcui 9997
  • empagliflozin
    first line
    sglt2_inhibitor
    10 mg PO daily • PO • daily
    triggers: euthyroid_persistent_lvef_below_40_egfr_above_20
    EMPULSE PMID 35347356; once euthyroid
    rxcui 1545653

outpatient playbook — drug actions (3)

  1. 1. lifelong levothyroxine maintenance
    rxcui 10582
    levothyroxine titrated to TSH 0.5-2.5 (young) or 0.5-4.0 (elderly) • PO • daily
    trigger: Iatrogenic hypothyroid (post-thyroidectomy or post-RAI)
    ATA 2014 PMID 25266247
  2. 2. continue GDMT 4-pillar if persistent HFrEF
    rxcui 1656328
    ARNI + BB + MRA + SGLT2i at max tolerated • PO • as scheduled
    trigger: Persistent HFrEF after euthyroid achieved
    TRED-HF PMID 30429051; do not withdraw GDMT even if EF normalizes
  3. 3. statin
    rxcui 83367
    atorvastatin 40 mg PO daily • PO • daily
    trigger: Hypothyroid hyperlipidemia + ASCVD risk
    AHA / ACC lipid 2026

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Post-total or completion thyroidectomy patient presenting with new HF, fatigue, weight gain, cold intolerance, or bradycardia — replacement gap or non-adherence; Post-RAI ablation for Graves disease (typically 3-12 mo prior) presenting with new HF or myxedema features — predictable iatrogenic hypothyroidism not yet replaced; Patient on methimazole or PTU for hyperthyroid with rapid TSH rise and new HF symptoms — over-treatment / overshoot.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Acute HF — Iatrogenic hypothyroid (post-thyroidectomy / post-RAI / over-treated thionamide)** (cardio.acute-hf.iatrogenic-hypothyroid.v1).
Scope: Iatrogenic hypothyroid HF = thyroid hormone deficiency from thyroidectomy / RAI / over-treated thionamide / central pituitary cause; impaired myocardial relaxation + reduced CO + bradycardia + pericardial effusion + hyperlipidemia accelerating CAD; severe form = myxedema coma (mortality 30-60%)

No severity triggers fired against current inputs.

Plan

Regimen axis: **Iatrogenic hypothyroid HF — STEROID FIRST then T4 replacement, cautious diuresis (mucinous edema not true volume), rate support, ADHF backbone**.
1. hydrocortisone 100 mg IV q8h until adrenal insufficiency excluded IV q8h (glucocorticoid_short_acting, first line) — ATA 2014 PMID 25266247 + Wartofsky myxedema management — MANDATORY before thyroid replacement; 5-10% concurrent adrenal insufficiency; T4 without cortisol can precipitate adrenal crisis
2. levothyroxine 200-500 µg IV LOAD (lower 100-200 µg if elderly/CAD/AF) then 50-100 µg IV daily until tolerating PO; PO maintenance 1.6 µg/kg IBW IV daily (thyroid_hormone_replacement, first line) — ATA 2014 PMID 25266247 — IV loading for myxedema; oral replacement once stable; titrate to TSH 0.5-2.5 in young, 0.5-4.0 in elderly
3. liothyronine (T3) 5-20 µg IV q8h adjunct (controversial; consider in severe myxedema coma) IV q8h (thyroid_hormone_t3, second line) — Wartofsky — adjunctive T3 may speed conversion in severe cases but increases cardiac risk; use cautiously in elderly/CAD
4. furosemide 20-40 mg IV bolus (LOWER than usual due to mucinous edema not true volume + hyponatremia risk) IV as needed (loop_diuretic, first line) — Cautious diuresis — peripheral edema in hypothyroid is often mucinous not volume; over-diuresis worsens hyponatremia + cardiac strain; DOSE PMID 21366472 strategy adapted
5. normal saline 0.9% 500 mL IV bolus over 30 min cautiously, then 75-100 mL/h maintenance IV as needed (crystalloid, first line) — Cautious crystalloid for hypotension; avoid free water due to hyponatremia; consider 3% saline if Na <120 with seizures
6. norepinephrine 0.05-0.5 µg/kg/min titrate to MAP ≥65 (often poorly responsive until thyroid + cortisol replacement) IV continuous (vasopressor_alpha_beta, first line) — SOAP-II PMID 20200382; vasopressor responsiveness improves with thyroid + cortisol replacement; may need higher than usual doses
7. atropine 0.5-1 mg IV q3-5 min up to 3 mg IV as needed (anticholinergic_muscarinic_antagonist, first line) — AHA ACLS bradycardia algorithm; bridge to thyroid replacement / pacing
8. isoproterenol 2-10 µg/min IV titrate IV continuous (beta_agonist, second line) — Beta-1 agonist bridge for refractory bradycardia until pacing or thyroid replacement effect
9. carvedilol 3.125 mg PO BID titrate (DEFER until euthyroid + no bradycardia) PO BID (beta_alpha_blocker, first line) — GDMT for persistent HFrEF; DEFER initiation until thyroid replacement complete + bradycardia resolved (BB worsens bradycardia in active hypothyroid); CAPRICORN PMID 11356436
10. sacubitril-valsartan 24/26 mg PO BID titrate (DEFER until euthyroid + stable hemodynamics) PO BID (arni, first line) — PIONEER-HF PMID 30403955; defer initiation until after thyroid replacement to avoid hypotension layering
11. spironolactone 12.5-25 mg PO daily PO daily (mra, first line) — RALES PMID 10471456; once euthyroid + stable
12. empagliflozin 10 mg PO daily PO daily (sglt2_inhibitor, first line) — EMPULSE PMID 35347356; once euthyroid

Setting playbook (outpatient) — Long-term endocrine + cardiac surveillance: TSH q3 mo until stable then annually; cardiology follow-up if persistent HF; lipid control; address ongoing iatrogenic context (RAI patients are lifelong hypothyroid; thyroidectomy patients require lifelong replacement)
13. lifelong levothyroxine maintenance levothyroxine titrated to TSH 0.5-2.5 (young) or 0.5-4.0 (elderly) PO daily — Iatrogenic hypothyroid (post-thyroidectomy or post-RAI) (ATA 2014 PMID 25266247)
14. continue GDMT 4-pillar if persistent HFrEF ARNI + BB + MRA + SGLT2i at max tolerated PO as scheduled — Persistent HFrEF after euthyroid achieved (TRED-HF PMID 30429051; do not withdraw GDMT even if EF normalizes)
15. statin atorvastatin 40 mg PO daily PO daily — Hypothyroid hyperlipidemia + ASCVD risk (AHA / ACC lipid 2026)

Non-pharmacologic actions:
- Endocrine clinic q3-6 mo then annual
- Cardiology clinic q6-12 mo if persistent HFrEF
- Cardiac rehab maintenance
- Lifelong replacement adherence reinforcement
- Pituitary follow-up if central hypothyroid

AVOID / contraindication checks:
- Hydrocortisone_before_levothyroxine_in_suspected_myxedema_coma (ATA 2014; precipitates adrenal crisis if 5 10% concurrent adrenal insufficiency)
- Lower_levothyroxine_load_in_elderly_cad_or_af_history (200 µg or less; arrhythmia + ischemia risk with rapid replacement)
- Avoid_active_external_rewarming_in_myxedema_coma (vasodilation + hypotension; passive rewarming preferred)
- Cautious_diuresis_in_hypothyroid_edema_likely_mucinous_not_volume (over diuresis worsens hyponatremia + cardiac strain)
- Avoid_free_water_in_severe_hyponatremia (use 0.9% saline; consider 3% saline only if Na <120 with neurologic symptoms)
- Correct_hyponatremia_slowly_no_more_than_8_meq_24h (osmotic demyelination risk)
- Defer_beta_blocker_initiation_until_euthyroid (worsens bradycardia in active hypothyroid)
- Defer_acei_arni_initiation_until_euthyroid_and_hemodynamically_stable (hypotension layering)
- Reduce_thionamide_dose_if_iatrogenic_overshoot (methimazole / PTU)
- Adequate_post_thyroidectomy_replacement_1.6_mcg_kg_ibw (prevent recurrence)
- Avoid_amiodarone_in_unstable_thyroid_state (worsens both hyper and hypothyroid)
- Check_drug_interactions_with_levothyroxine_absorption_ppi_iron_calcium_food_separation_4h

Monitoring

Regimen monitoring:
- continuous telemetry for bradycardia av block qt prolongation
- q6h vitals with core temperature (hypothermia trend)
- q4h neuro checks in myxedema coma (mental status improvement marker)
- daily bmp with sodium correction no more than 8 meq 24h
- daily tsh and free t4 during acute phase then q4 6 weeks
- q6h glucose during hydrocortisone
- q12h ck until trending down if rhabdomyolysis
- daily echo if pericardial effusion present for tamponade surveillance
- cortisol baseline and acth stim when clinically safe (if borderline)
- tsh at 4 6 weeks post replacement change (slow equilibration)
- lipid panel at 3 mo after euthyroid (cholesterol normalizes with replacement)

Setting (outpatient) monitoring:
- Quarterly TSH initially then annual
- Annual lipid + cardiac risk assessment

Follow-up plan: Endocrinology clinic at 2 weeks then q4-6 weeks during titration; TSH at 4-6 weeks then q3 mo once stable; cardiac follow-up for any persistent dysfunction; address iatrogenic trigger (thionamide dose adjustment, RAI follow-up replacement schedule, post-thyroidectomy lifelong replacement education); lipid management; pituitary follow-up if central hypothyroid
- Close-out criterion: endocrinology + replacement-titration plan + iatrogenic-trigger-addressed plan documented

Monitoring phase: Continuous telemetry (bradycardia, AV block, QT prolongation), q6h vitals + temperature + mental status, daily BMP (sodium correction not too rapid), daily TSH + free T4 trend (peaks slow over weeks), q6h glucose during hydrocortisone, daily echo if pericardial effusion present, neuro checks q4h in myxedema coma

Disposition

Current setting: outpatient — Long-term endocrine + cardiac surveillance: TSH q3 mo until stable then annually; cardiology follow-up if persistent HF; lipid control; address ongoing iatrogenic context (RAI patients are lifelong hypothyroid; thyroidectomy patients require lifelong replacement)

Disposition criteria:
- Long-term stable; cross-link to cardio.hfref.core.v1 if HFrEF persists; lifelong endocrine surveillance

Escalation triggers (move to higher acuity):
- TSH drift outside target → dose adjustment + adherence + interaction check
- Recurrent HF decompensation → cardiology + endo urgent
- New AF or arrhythmia → cardiology

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Iatrogenic hypothyroid patient with hypothermia + altered mentation + bradycardia + hypotension + hyponatremia — myxedema coma with shock (mortality 30-60%)
- [LIFE_THREATENING] Iatrogenic hypothyroid patient with concurrent adrenal insufficiency (5-10% in myxedema coma; central hypothyroid with pituitary cause has high overlap)
- [LIFE_THREATENING] Sodium <120 mEq/L with seizure or neurologic symptoms in myxedema patient OR rapid sodium correction (>8 mEq/24h) with osmotic demyelination risk

Citations

- ATA 2014 hypothyroidism + Klein 2007 thyroid heart NEJM + Wartofsky myxedema coma + AACE thyroid + 2022 ACC/AHA HF [PMID:25266247](https://pubmed.ncbi.nlm.nih.gov/25266247/)
- Cited evidence (PMID 17314344) [PMID:17314344](https://pubmed.ncbi.nlm.nih.gov/17314344/)
- Cited evidence (PMID 35363499) [PMID:35363499](https://pubmed.ncbi.nlm.nih.gov/35363499/)
- Cited evidence (PMID 34447992) [PMID:34447992](https://pubmed.ncbi.nlm.nih.gov/34447992/)
- Cited evidence (PMID 38264914) [PMID:38264914](https://pubmed.ncbi.nlm.nih.gov/38264914/)

Last reconciled with current guidelines: 2026-05-15.
References